%0 Journal Article
%T Levodopa-carbidopa-entacapone overdose presenting as altered mental status, xanthoderma, and yellowish sclera
%A CHO
%A SUK JIN
%A CHOI
%A SEUNG WOON
%A KANG
%A TAE KYUNG
%A KIM
%A HYE JIN
%A LEE
%A SUN HWA
%A OH
%A SUNG CHAN
%A RYU
%A SEOKYONG
%A YUN
%A SEONG JONG
%J -
%D 2018
%R 10.22514/SV142.102018.12
%X Sa£¿etak Levodopa-carbidopa-entacapone is a single combination drug consisting of levodopa (aromatic amino acid), carbidopa (dopa-decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase inhibitor). The Food and Drug Administration approved levodopa-carbidopa-entacapone in 2003, as treatment for idiopathic Parkinson¡¯s disease in patients experiencing signs and symptoms of wearing-off. Although various adverse drug reactions of levodopa-carbidopa-entacapone have been recorded, there has been no reported case of levodopa-carbidopa-entacapone overdose. We report the first case of signs and symptoms of an overdose of levodopa-carbidopa-entacapone (levodopa: 3000 mg; carbidopa: 750 mg; entacapone: 6000 mg) in a suicide attempt, presenting as altered mentality, xanthoderma, and yellowish sclera without hyperbilirubinemia
%K levodopa-carbidopa-entacapone
%K Parkinson¡¯s disease
%K drug overdose
%K xanthoderma
%K yellowish sclera
%K toxicology
%U https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=317559